Literature DB >> 6124405

The metabolic disposition of the selective beta 1-adrenoceptor agonist prenalterol in mice, rats, dogs, and humans.

K J Hoffmann, A Arfwidsson, K O Borg.   

Abstract

The metabolic routes of the selective beta 1-adrenoceptor agonist prenalterol have been studied in mice, rats, dogs, and humans after oral administration. The drug was well absorbed from the gastrointestinal tract and most of the administered radioactivity was excreted in urine from all species within 24 hr. Prenalterol was metabolized to a varying extent in the species studied. About 20% of the 10-mg dose was recovered unchanged in man, the corresponding figures being 1.8% in the mouse, 7% in the rat, and 54% in the dog at 0.263 mg/kg (1 mumol/kg). Three metabolites were characterized and quantified by thin-layer chromatography, high-performance liquid chromatography, nuclear magnetic resonance (1H and 13C), and gas chromatography-mass spectrometry. Pronounced species variations in the metabolic pattern were observed. The phenolic sulfate ester of prenalterol was the main urinary metabolite in man, important in the dog, minor in the rat but not detectable in the mouse. Prenalterol glucuronide was formed in significant amounts in the animals and, in addition, beta-4(hydroxyphenoxy)lactic acid was present in dog urine. In the rat and the mouse the degree of biotransformation of prenalterol was significantly decreased at high oral doses of 2630 mg/kg (10 mmol/kg). The synthesis of prenalterol sulfate ester with use of ion pair extraction techniques is described.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124405

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

1.  Stereoselective metabolism of RS-albuterol in humans.

Authors:  T Walle; E A Eaton; U K Walle; G R Pesola
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

2.  Stereoselective sulphate conjugation of racemic terbutaline by human liver cytosol.

Authors:  T Walle; U K Walle
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

3.  Pharmacokinetics of prenalterol after single and multiple administration of controlled release tablets to patients with congestive heart failure.

Authors:  U Dahlström; C Graffner; U Jonsson; K J Hoffmann; E Karlsson; P O Lagerström
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  The metabolic fate of 2H-labelled propafenone in man.

Authors:  H G Hege; M Hollmann; S Kaumeier; H Lietz
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jan-Mar       Impact factor: 2.441

Review 5.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.